Stockreport

SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

SAB Biotherapeutics, Inc.  (SABS) 
PDF MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglo [Read more]